Login to Your Account



Financings Roundup


Monday, November 5, 2012
• Isconova AB, of Uppsala, Sweden, carried out a fully subscribed rights issue of about SEK50 million (US$7.4 million) to finance clinical trials in-house, increase production capacity and continue research in new indications for the adjuvant Matrix M.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription